Señales en vivo de SPHRY | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (2 may 2024 @ 14:12):

Stats
Volumen de hoy	1 000.00
Volumen promedio	1 919.00
Capitalización de mercado	30.90M
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-5.36
ATR14	$0 (0.00%)

Starpharma Holdings Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Starpharma Holdings Finanzas

Annual	2023
Ingresos:	$2.94M
Beneficio Bruto:	$1.22M (41.60 %)
EPS:	$-0.0382

FY	2023
Ingresos:	$2.94M
Beneficio Bruto:	$1.22M (41.60 %)
EPS:	$-0.0382

FY	2022
Ingresos:	$4.68M
Beneficio Bruto:	$1.91M (40.71 %)
EPS:	$-0.0397

FY	2021
Ingresos:	$1.80M
Beneficio Bruto:	$1.01M (56.01 %)
EPS:	$-0.530

Financial Reports:

No articles found.

Starpharma Holdings

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, the company develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase II clinical trial, and DEP irinotecan that is in phase II clinical trials for the treatment of cancer; oncology programs, such as DEP radiopharmaceuticals, DEP HER-2 ADC, and DEP gemcitabine; DEP non-oncology candidates; and DEP AZD0466, which is in Phase I/II clinical trials to treat haematological tumours. The company was founded in 1996 and is headquartered in Abbotsford, Australia.